 Alkindi 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
II/0019 
Update of section 4.2 of the SmPC in order to update 
14/12/2023 
25/01/2024 
SmPC and PL 
posology recommendations in case of incomplete 
dosing, following the request by PRAC in the AR for 
procedure PSUSA/00010674/202208; the Package 
Leaflet is updated accordingly. 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
 
 
IA/0022 
B.III.1.a.2 - Submission of a new/updated or 
24/01/2024 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0020 
C.I.11.z - Introduction of, or change(s) to, the 
06/11/2023 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IA/0018/G 
This was an application for a group of variations. 
12/05/2023 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IB/0017 
B.II.b.5.z - Change to in-process tests or limits 
04/04/2023 
n/a 
applied during the manufacture of the finished 
product - Other variation 
PSUSA/10674
Periodic Safety Update EU Single assessment - 
16/03/2023 
n/a 
PRAC Recommendation - maintenance 
/202208 
hydrocortisone (centrally authorised products for 
adrenal insufficiency, paediatric use only) 
R/0014 
Renewal of the marketing authorisation. 
15/09/2022 
09/11/2022 
SmPC, 
Labelling and 
PL 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10674
Periodic Safety Update EU Single assessment - 
10/03/2022 
n/a 
PRAC Recommendation - maintenance 
/202108 
hydrocortisone (centrally authorised products for 
adrenal insufficiency, paediatric use only) 
IAIN/0013/G 
This was an application for a group of variations. 
07/02/2022 
09/11/2022 
Annex II and 
PL 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0011 
C.I.z - Changes (Safety/Efficacy) of Human and 
03/05/2021 
19/05/2021 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
PSUSA/10674
Periodic Safety Update EU Single assessment - 
11/03/2021 
n/a 
PRAC Recommendation - maintenance 
/202008 
hydrocortisone (centrally authorised products for 
adrenal insufficiency, paediatric use only) 
PSUSA/10674
Periodic Safety Update EU Single assessment - 
03/09/2020 
n/a 
PRAC Recommendation - maintenance 
/202002 
hydrocortisone (centrally authorised products for 
adrenal insufficiency, paediatric use only) 
PSUSA/10674
Periodic Safety Update EU Single assessment - 
12/03/2020 
n/a 
PRAC Recommendation - maintenance 
/201908 
hydrocortisone (centrally authorised products for 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
adrenal insufficiency, paediatric use only) 
IB/0007 
C.I.z - Changes (Safety/Efficacy) of Human and 
16/10/2019 
09/03/2020 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II and PL 
PSUSA/10674
Periodic Safety Update EU Single assessment - 
05/09/2019 
n/a 
PRAC Recommendation - maintenance 
/201902 
hydrocortisone (centrally authorised products for 
adrenal insufficiency, paediatric use only) 
IAIN/0005/G 
This was an application for a group of variations. 
11/03/2019 
09/03/2020 
SmPC, Annex 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
II, Labelling 
and PL 
PSUSA/10674
Periodic Safety Update EU Single assessment - 
14/02/2019 
n/a 
PRAC Recommendation - maintenance 
/201808 
hydrocortisone (centrally authorised products for 
adrenal insufficiency, paediatric use only) 
T/0003 
Transfer of Marketing Authorisation 
06/08/2018 
06/09/2018 
SmPC, 
Labelling and 
PL 
IB/0002/G 
This was an application for a group of variations. 
29/06/2018 
06/09/2018 
SmPC 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
IAIN/0001/G 
This was an application for a group of variations. 
03/05/2018 
06/09/2018 
Annex II and 
PL 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 5/5 
 
 
 
 
 
 
 
 
 
 
